Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI) Sees Large Increase in Short Interest

Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI) saw a significant growth in short interest in April. As of April 15th, there was short interest totalling 1,430,000 shares, a growth of 859.7% from the March 31st total of 149,000 shares. Based on an average trading volume of 632,000 shares, the short-interest ratio is presently 2.3 days.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Calidi Biotherapeutics stock. Spectrum Asset Management Inc. NB CA purchased a new position in shares of Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 166,494 shares of the company’s stock, valued at approximately $94,000. Spectrum Asset Management Inc. NB CA owned about 0.47% of Calidi Biotherapeutics at the end of the most recent reporting period. Institutional investors own 12.53% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on CLDI shares. Robert W. Baird dropped their target price on shares of Calidi Biotherapeutics from $9.00 to $4.50 and set an “outperform” rating on the stock in a report on Thursday, March 21st. HC Wainwright dropped their target price on shares of Calidi Biotherapeutics from $11.00 to $2.00 and set a “buy” rating on the stock in a report on Thursday, March 21st.

Calidi Biotherapeutics Trading Up 0.4 %

Shares of Calidi Biotherapeutics stock opened at $0.16 on Friday. Calidi Biotherapeutics has a 1-year low of $0.14 and a 1-year high of $13.79.

About Calidi Biotherapeutics

Calidi Biotherapeutics, Inc, a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors.